Dosages of Tirzepatide: Choosing the Right Step for You

Why tirzepatide starts low and climbs slowly

The most common question our prescribers hear is some version of: "why am I starting at 2.5 mg when the medicine clearly works at higher doses?" It is a fair question. The answer is that the gastrointestinal side effects (nausea especially) are dose-related. Beginning at 2.5 mg gives your system a gentler introduction. The full picture on Mounjaro covers the mechanism in detail, but in short: tirzepatide slows gastric emptying and acts on two gut-hormone receptors simultaneously. That's powerful, and power introduced too fast tends to cause discomfort.

So the opening pen isn't about results. It is about making the weeks that follow tolerable. Most people notice appetite changes during this period anyway, even if weight loss is modest. The structured titration that follows (typically one step every four weeks) is where the clinical work happens. If you want to understand how each step fits into the overall plan, our guide to Mounjaro dosages walks through the full sequence, and according to NHS guidance on tirzepatide, the schedule runs 2.5 mg → 5 mg → 7.5 mg → 10 mg → 12.5 mg → 15 mg, with each step contingent on tolerability. Nobody is pushed through faster than that.

One practical note worth flagging: if your prescription start date falls near a bank holiday or you're ordering close to a monthly budget reset, factor in that same-day dispatch requires orders placed before 12pm Monday to Friday. Your prescriber's timing decisions don't change, but the logistics around delivery can.

What actually determines which dosage you reach

Not everyone ends up at 15 mg, and that's not a failure. The goal is the highest well-tolerated dose, not the highest dose on the list. A prescriber reviewing your case will weigh side-effect history, weight-loss trajectory, and any underlying health conditions. If 10 mg is producing good results with minimal discomfort, there may be little clinical reason to push further. If side effects at a given step are persistent, the prescriber might keep you at the lower level longer before any increase.

NICE's technology appraisal of tirzepatide (TA1026) notes that treatment should be reviewed if less than 5% weight loss is achieved after six months at the highest tolerated dose. That review criterion matters: it means the dosage question never really closes. It stays open throughout treatment, and our detailed tirzepatide dosage page covers how individual steps are assessed in more depth, alongside the 5 mg dosage and 10 mg dosage pages, for instance, which go through what to expect at those points.

Weight-related conditions also play a role. Adults with a BMI of 27 or above who have a qualifying condition (hypertension, obstructive sleep apnoea, type 2 diabetes, high cholesterol and others) are eligible for the licensed dose range just as adults with a BMI of 30 or above are. Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance. None of this changes the six-dose structure; it affects who has access to it.

The dosage decision at each repeat, what clinical re-review means

Each time you reorder through a regulated pharmacy, a prescriber checks whether the current dose remains appropriate. That review is not a rubber stamp. It looks at how you've responded, whether side effects have settled, and whether a dose increase is clinically supported. At nume, that review is carried out by a GPhC-registered prescriber, reading your case personally the same day.

Evidence for dose increases is part of that review. Moving from, say, 7.5 mg to 10 mg isn't automatic at the four-week mark, the prescriber needs to see that the previous step was tolerated and that the clinical picture supports moving forward. This structure is what separates regulated treatment from the counterfeit pens circulating online, which carry no such oversight and have been the subject of multiple MHRA enforcement actions.

For a fuller breakdown of costs across the dosage range, the Mounjaro cost page covers what private treatment typically involves at each pen strength. Understanding the pricing structure alongside the dosage structure helps you plan realistically. Neither is hidden at a reputable provider.

Staying at a dose, and what happens if a dose doesn't suit you

Some people find a comfortable level and stay there for months. That is entirely appropriate. The titration schedule is a ceiling, not a conveyor belt. If 7.5 mg is your best-tolerated dose and weight loss is progressing, remaining there is a legitimate clinical position. Similarly, if a dose increase brings side effects that don't settle, a prescriber might step back down temporarily. Dose reduction is an option; it is not discussed enough.

Side effects at any tirzepatide dosage are mostly gastrointestinal, nausea, looser stools, reflux, reduced appetite to the point of forgetting meals. They tend to be most pronounced in the first week or two after a dose step and ease as your body adjusts. The Patient Information Leaflet that arrives with each pen gives the full list; your prescriber and the nume FAQs are there if questions come up between doses.

If you're considering starting treatment or want a clinical view on your current dose, our free consultation is the place to start. A prescriber will review your situation and take it from there.